Clarity Pharmaceuticals (ASX:CU6): SECuRE Trial Recruitment and Diagnostic Programs

Aditi Sarkar

03 November 2026 05:53 PM AEDT

Clarity Pharmaceuticals (ASX:CU6): SECuRE Trial Recruitment and Diagnostic Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

The SECuRE trial achieved its main-group recruitment target of 16 participants in October 2026.
SECuRE is evaluating copper-67 SAR-bisPSMA treatment in advanced prostate cancer.
The company also has Phase III diagnostic programs involving copper-64 SAR-bisPSMA.
Its investigational products remain subject to clinical assessment and regulatory review.

Clarity Pharmaceuticals Limited (ASX:CU6) develops copper-based radiopharmaceutical candidates for cancer imaging and treatment using its targeted copper theranostic technology. Shares ended 3 November 2026 at AUD 1.47, while attention in the company’s latest reports remains on the progress and financial implications of its 2026 activities.

Prostate Cancer Therapy Program

Clarity Pharmaceuticals (ASX:CU6) reported in October that the main-group recruitment target of 16 patients had been achieved in the cohort-expansion stage of its Phase I/IIa SECuRE trial. The study evaluates copper-67 SAR-bisPSMA in metastatic castration-resistant prostate cancer, with a separate group examining combination treatment with enzalutamide. Enrolment and treatment are milestones in the evidence-generation process, not proof of approval or commercial availability.

The product platform pairs copper-64 imaging with copper-67 therapy, linking diagnostic selection and therapeutic investigation. Company updates have disclosed preliminary safety and activity observations from treated patients; the results are drawn from a limited early-stage study population. They require interpretation within the trial design and follow-up periods rather than extrapolation to all patients with prostate cancer.

Diagnostic Trials and Regulatory Process

Clarity (ASX:CU6) is also developing copper-64 SAR-bisPSMA imaging programs. Its CLARIFY Phase III study evaluates diagnostic performance in patients with prostate cancer ahead of surgery, while AMPLIFY addresses biochemical recurrence after prior treatment. The trials have distinct patient populations and objectives. Completion of recruitment, availability of results and subsequent regulatory filings are separate steps.

The company has additionally described copper-based imaging research in neuroendocrine tumours through its SARTATE program. For clinical-stage developers, trial recruitment, imaging interpretation, independent review and Manufacturing readiness can all affect the timing and cost of development. There is no guarantee that positive early results will translate into regulatory approvals or commercial sales.

Operating Risks and Financial Context

For Clarity Pharmaceuticals Limited (ASX:CU6), the most useful assessment separates Business activity from financial outcomes. The distinction between an announced milestone and a completed commercial or financial outcome is important. Management disclosures can describe objectives, progress and planned next steps, but reported results provide the evidence of what was achieved during a particular period. Comparing successive reporting periods on the same accounting or operational basis helps avoid misleading conclusions. Sector-wide conditions can influence a business without demonstrating that they caused a particular daily share-price movement.

What to Watch Next

Important areas for the next published updates include SECuRE follow-up, diagnostic Phase III readouts, regulator interactions and the cash required to continue clinical development. Each may affect the interpretation of the company’s progress, but none should be treated as a forecast of profitability, trial success or share-price performance. The timing of disclosures also matters because the information available at 3 November 2026 may not cover every development later in the financial year.

Key Insights

Clarity Pharmaceuticals Limited (ASX:CU6) has reported developments during 2026 that relate to its operating model, financial resources and management priorities. Its latest disclosed measures need to be interpreted on their stated reporting basis. The next company updates may clarify the pace of activity, associated costs and the extent to which operational progress translates into recognised revenue, clinical evidence or available cash, as relevant to the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.